FINANCIAL CHRONICLE™
Dear Reader,

Registration with the Sri Lanka FINANCIAL CHRONICLE™️ would enable you to enjoy an array of other services such as Member Rankings, User Groups, Own Posts & Profile, Exclusive Research, Live Chat Box etc..

All information contained in this forum is subject to Disclaimer Notice published.


Thank You
FINANCIAL CHRONICLE™️
www.srilankachronicle.com


Join the forum, it's quick and easy

FINANCIAL CHRONICLE™
Dear Reader,

Registration with the Sri Lanka FINANCIAL CHRONICLE™️ would enable you to enjoy an array of other services such as Member Rankings, User Groups, Own Posts & Profile, Exclusive Research, Live Chat Box etc..

All information contained in this forum is subject to Disclaimer Notice published.


Thank You
FINANCIAL CHRONICLE™️
www.srilankachronicle.com
FINANCIAL CHRONICLE™
Would you like to react to this message? Create an account in a few clicks or log in to continue.
FINANCIAL CHRONICLE™

Encyclopedia of Latest news, reviews, discussions and analysis of stock market and investment opportunities in Sri Lanka

Click Link to get instant AI answers to all business queries.
Click Link to find latest Economic Outlook of Sri Lanka
Click Link to view latest Research and Analysis of the key Sectors and Industries of Sri Lanka
Worried about Paying Taxes? Click Link to find answers to all your Tax related matters
Do you have a legal issues? Find instant answers to all Sri Lanka Legal queries. Click Link
Latest images

Latest topics

» Japanese Gratitude to Sri Lanka (日本の感謝)
by God Father Today at 12:13 am

» Maharaja Foods PLC (MFL) - IPO Analysis
by ChooBoy Mon Jul 22, 2024 12:27 am

» කොළඹ කොටස් වෙළඳපොල විශ්ලේෂණය - 2024
by ChooBoy Fri Jul 19, 2024 11:53 am

» Winds of Change: Sri Lanka's Banking Crisis is Stalling Renewable Energy Ambitions of Local Stalwarts of Wind & Solar Power
by God Father Wed Jul 17, 2024 10:11 pm

» Banking Sector Analysis
by God Father Sat Jul 13, 2024 7:57 am

» Impact of Elections on Colombo Stock Market Sentiment
by Quibit Tue Jul 09, 2024 9:01 am

» LankaBIZ Unveils AI-Driven On-Demand Financial Research and Analysis Service
by Quibit Thu Jul 04, 2024 12:49 pm

» CDB Non voting
by Nandun Sun Jun 30, 2024 9:45 pm

» The Parsi Power Play: How a Small Community of Iranian Parsis are Controling Sri Lanka's US $ 85 billion Economy & 22 Million Population & Politics driving away FDIs
by MalakaDesmond Sun Jun 30, 2024 10:19 am

» Richard Pieris Group: Mismanaged?
by Walbaba Sat Jun 29, 2024 7:04 pm

» සොෆ්ට්ලොජික් හෝල්ඩිංග්ස් පීඑල්සී: අඳුරු අපේක්ෂාවන් සහිත ඉහළ අවදානම් ආයෝජනයක්
by D.G.Dayaratne Tue Jun 25, 2024 5:45 am

» සොෆ්ට්ලොජික් ප්‍රාග්ධනයට වන්දි ගෙවන Share BuyBack නිසා Softlogic ජීවිත රක්‍ෂණය බංකොලොත් වීමේ අවදානමක
by MalakaDesmond Tue Jun 25, 2024 1:49 am

» Softlogic Life insurance face Danger of Bankruptcy due to Share BuyBack that compensate Softlogic Capital
by MalakaDesmond Tue Jun 25, 2024 1:33 am

» Softlogic Holdings PLC: A High-Risk Investment with Bleak Prospects
by MalakaDesmond Tue Jun 25, 2024 12:52 am

» FINANCE AND LEASING SECTOR
by SL-INVESTOR Sat Jun 22, 2024 12:48 am

» HSENID BUSINESS SOLUTIONS PLC (HBS.N0000)
by ErangaDS Wed Jun 19, 2024 9:21 pm

» How will proposed Tax Reforms affect Sri Lankans in 2025
by Quibit Wed Jun 19, 2024 9:27 am

» Falsified accounts and financial misrepresentation at Arpico Insurance PLC (AINS)
by ChooBoy Tue Jun 18, 2024 11:31 pm

» Impact of IMF reforms to Sri Lanka Economy
by D.G.Dayaratne Mon Jun 17, 2024 6:36 pm

» Richard Pieris Finance Ltd continue to endanger the Depositors with negative performance
by ddindika Mon Jun 17, 2024 3:17 pm

» Richard Pieris Exports reports 97% decline in Net Profits
by Biggy Sat Jun 15, 2024 11:26 am

» Do your own Stock Market Research using AI Tools
by Quibit Fri Jun 14, 2024 10:50 am

» What will happen tomorrow?
by cheetah Thu Jun 13, 2024 12:07 pm

LISTED COMPANIES

Submit Post
ශ්‍රී ලංකා මූල්‍ය වංශකථාව - සිංහල
Submit Post


CONATCT US


Send your suggestions and comments

* - required fields

Read FINANCIAL CHRONICLE™ Disclaimer



EXPERT CHRONICLE™

ECONOMIC CHRONICLE

GROSS DOMESTIC PRODUCT (GDP)



CHRONICLE™ YouTube


You are not connected. Please login or register

Global COVID cases rise as BA.4 and BA.5 expand

Go down  Message [Page 1 of 1]

samaritan

avatar
Moderator
Moderator

Global COVID cases rise as BA.4 and BA.5 expand Covid_testing_in_puerto_rico-natl_guard

COVID-19 cases jumped 18% last week and are at their highest levels since April, and the increase comes as the more transmissible Omicron BA.4 and BA.5 subvariants cause most infections, the World Health Organization (WHO) said today in its latest update.

BA.4, BA.5 make up 55% of global samples

Four of the six WHO regions saw rises last week: the Eastern Mediterranean, Europe, Southeast Asia, and the Americas. Globally, deaths stayed level, but were up in the Eastern Mediterranean, Southeast Asian, and Americas regions.
About 4.1 million cases were reported to the WHO last week, likely an undercount given reduced testing in many countries. The United States, Germany, Brazil, Italy, and China reported the most cases.
At a briefing today of the WHO's Pan American Health Organization (PAHO), officials said cases rose in all four subregions in the Americas, with a jump of 24.6% in South America. Cases in North America rose 7.7% last week, mainly due to rises in the United States and Mexico.
The WHO said BA.4 and BA.5 subvariants continue to make up an increasing proportion of sequenced samples. Both share a mutation linked to greater transmissibility, and early indications suggest that evolutionary changes increase immune escape following infection or vaccination.
Combined, BA.4 and BA.5 made up 55% of sequenced samples. For the week ending Jun 19, BA.5 represented 43% of samples, up from 28% the week before. And BA.4 represented 12% of sequenced samples, up from 9% the previous week.

Pandemic changing 'but it's not over'

At a WHO briefing today, Director-General Tedros Adhanom Ghebreyesus, PhD, said cases are rising in 110 countries, fueled by BA.4 and BA.5 in many countries. "This pandemic is changing but it's not over. We have made progress, but it's not over." He reiterated his concerns about reduced testing and genetic sequencing, which reduces the world's ability to track outbreak and virus changes.
Taking stock of the world's vaccination status, Tedros said only 58 countries have reached the mid-year target of vaccinating at least 70% of their population, with the average rate in low-income countries at 13%. He urged countries to vaccinate 100% of their health workers and people over 60 as soon as possible, noting that 75% of the group is now vaccinated.
For the general population, Tedros said it's important to keep strengthening immunity, which helps reduce severity and longer-term impacts from the disease. "Even relatively 'mild' cases are disruptive and damaging, keeping children out of school and adults from work, which causes further economic and supply chain disruption," he said.

Critical need for next-generation vaccines

Tedros said though it makes sense to update vaccines to cover evolving variants, the pace of mutation means the world continues to play catch-up. Second-generation vaccines that stop or reduce infection would be a major step forward, but ideally, the solution is a pan-coronavirus vaccine that covers current and future variants, he said.
In a related development, BioNTech said today that it and Pfizer would begin human trials of a pan-coronavirus vaccine in the second half of the year, according to Reuters, which cited slides from the company's investor day.

US booster uptake lags

Booster uptake is lukewarm in some US age-groups, according to an ABC News report that looked at federal data. Less than 10% of eligible children ages 5 to 11 have received a booster dose, and just 28.7% of adolescents ages 12 to 17 have gotten an extra dose. And less than 40% of eligible adults ages 18 to 49 have received a third dose.
The 7-day average for new daily cases is 113,849, with daily deaths averaging 385, according to the Washington Post tracker. Cases are up 21% in the past week, with deaths up by 41% and hospitalizations rising by 8%.
In other US developments, Eli Lilly said today that it would supply an additional 150,000 doses of bebtelovimab, a monoclonal antibody treatment under emergency use authorization for the treatment of mild-to-moderate COVID-19 infections in people ages 12 and older.
The drug continues to show neutralization activity against emerging Omicron variants, including BA.4 and BA.5. The purchase is worth $275 million and is expected to meet demand through late August.

https://www.cidrap.umn.edu/news-perspective/2022/06/global-covid-cases-rise-ba4-and-ba5-expand

Share this post on: reddit

No Comment.

Back to top  Message [Page 1 of 1]

Permissions in this forum:
You cannot reply to topics in this forum